What happened with NYXH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Nyxoah SA makes Genio for adults with moderate-to-severe obstructive sleep apnea, whose airway repeatedly closes during sleep. A surgically implanted device stimulates the nerves controlling the tongue on both sides to help keep the airway open. An external unit powers the implant, so it does not need an implanted battery.
Hospitals and distributors buy Genio, its only commercial product and the source of all its revenue. Nyxoah sells directly in most target markets and trains physicians and supports implantation and follow-up care. Sales have so far been limited and mostly in Germany; commercialization has also begun in the United States. Sales depend on physicians recommending the treatment, patients accepting surgery, and government or private insurers covering the system and associated care.
Genio has European CE marking and U.S. FDA approval, but Nyxoah can promote it only for authorized uses and needs local authorization to enter additional countries. It also relies on single-source suppliers for most components. Continued operations depend on securing additional funding, which is not assured.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Inspire Medical Systems, Inc. and Nyxoah compete for hospitals buying implants that stimulate the tongue’s nerve to treat moderate-to-severe obstructive sleep apnea, and each has challenged the other’s patents. Watch Inspire’s hospital and surgery-center sales and the patent cases involving Genio and Inspire IV/V.
LivaNova PLC is developing aura6000, a tongue-nerve stimulation treatment that would compete with Nyxoah’s Genio implants sold to hospitals and distributors. Its existing sales also include heart-lung machines and nerve-stimulation devices for epilepsy and depression, so watch aura6000’s U.S. approval and launch progress rather than treating all LivaNova sales as an OSA signal.
Apnimed, Inc.’s proposed oral treatment Oxnimbi (AD109) could replace Nyxoah’s implanted Genio therapy for some adults with obstructive sleep apnea. Apnimed has no marketed product sales yet; watch the FDA review, with a decision target of February 28, 2027.
ResMed Inc.’s first-line treatment comes before Nyxoah’s second-line implants: it sells systems to healthcare providers and patients that send pressurized air through a mask, known as CPAP. Watch whether patients can keep using those systems, since better-tolerated PAP treatment could reduce demand for Genio.
Eli Lilly & Co.’s Zepbound treats moderate-to-severe obstructive sleep apnea in patients with obesity, which could reduce demand for Nyxoah’s Genio or make more patients eligible for implants through weight loss. Watch whether these patients still need OSA treatment after losing weight; Nyxoah says it had not yet seen the potential expansion in implant eligibility.
Vivos Therapeutics, Inc.’s oral appliances and sleep-disorder treatments offer some OSA patients an alternative to Nyxoah’s Genio implants. Watch appliance sales separately from the fees Vivos earns for managing diagnostic and consulting services at sleep practices: the latter are not sales of a competing device.
Eli Lilly & Co. earningsLLY
Eli Lilly's report can show how strong demand is for Zepbound, which could reduce some patients' need for Nyxoah's Genio implant or leave more patients eligible for an implant after weight loss.
Read Zepbound sales alongside any specific information Lilly provides about people with obstructive sleep apnea (OSA). Stronger sales would show wider use of a treatment for patients with obesity, but not whether those patients still need Genio after losing weight: treatment could reduce implant demand, while patients whose OSA remains could still be eligible. Weaker sales would mean less near-term pressure from this alternative, not proof that Genio demand is stronger.
ResMed Inc. earningsRMD
ResMed's report will show demand for its mask-based pressurized-air treatment, a clue to the first-line option patients encounter before Nyxoah's Genio implant.
Read ResMed's sales of continuous positive airway pressure (CPAP) systems—masks that deliver pressurized air—alongside its comments on demand. Strong demand would show that this first-line treatment remains a draw, potentially keeping some patients from reaching Nyxoah's second-line implant. Weak demand could mean less pull from CPAP, but would not prove patients are switching to Genio or unable to continue CPAP.
Inspire Medical Systems, Inc. earningsINSP
Inspire Medical Systems, Inc.'s report will show whether hospitals and surgery centers are buying more of its nerve-stimulation implants, a direct read on the competition Nyxoah faces for Genio.
Read Inspire's sales to hospitals and surgery centers. Stronger sales would show providers buying more of an implant that treats moderate-to-severe OSA, intensifying the competition Nyxoah faces for Genio placements. Weaker sales could point to softer demand for implants overall; it would not mean patients automatically shift to Genio.
Nyxoah SA earningsThis company
Nyxoah sells only Genio to hospitals and distributors, so this report shows whether wider commercialization is generating enough sales and gross profit to support its costly expansion.
Read Genio revenue alongside the cost of goods sold: if revenue grows faster, gross profit—the amount left after those direct costs—increases; if costs catch up with or outpace revenue, added sales are not leaving more behind. Then compare gross profit with operating expenses and cash use. A narrowing gap would show expansion becoming more self-supporting; widening losses and cash use would mean growth still depends on outside funding. Some revenue tied to U.S. patient-related components and later disposable-patch deliveries is recognized only when delivered, so shipment timing may not match reported revenue.
